

#### Editorial Request Table – Revise

To the Author — Please review the editorial comments and requests below and implement all necessary changes.

Please note that manuscripts that do not comply with these requests may be returned to the authors if the editors determine that the lack of compliance may hinder the peer-review process or make a disadvantageous outcome more likely.

| General   | Author confirmation |
|---|---------------------|
| An editorial policy checklist that verifies compliance with all required editorial policies must be completed and uploaded with the revised manuscript. All points on the policy checklist must be addressed; if needed, please revise your manuscript in response to these points. https://www.nature.com/documents/nr-editorial-policy-checklist.zip  | X                   |
| Please note that this form is a dynamic 'smart pdf' and must therefore be downloaded and completed in Adobe Reader. Clicking this link will download a zip file containing the pdf.   |                     |
| We will not be able to process the manuscript further if we have not received an editorial policy checklist.  |                     |
| A reporting summary must be uploaded with your manuscript. You can find the Reporting Summary form, it here: https://www.nature.com/documents/nr-reporting-summary.zip  The reporting summary will be published alongside your manuscript therefore it needs to accurately represent your work.  Also, please make sure to include a date at the top of the document. The reporting summary is visible to referees; if you opted for double-anonymized peer review, don't include your name or signature.   | X                   |
| We discourage parachute science, where none of the participants of a research project are based near the location under investigation (if it is inhabited). We are seeking to understand in more depth why this occurs. If your study location is inhabited, and none of the authors of the manuscript are local, please explain why local researchers were not involved in the project. Please include an Ethics and Inclusion statement. https://www.nature.com/nature-portfolio/editorial-policies/authorship#authorship-inclusion-and-ethics-in-global-research | X                   |

| Main Text   | Author confirmation |
|---|---------------------|
| Format:  Please ensure your manuscript includes the following sections, presented in this order and with the following headings:  Abstract (250 words)  Introduction  Methods  Results  Discussion, with mandatory subheading: Limitations.  Data Availability Statement  Code Availability Statement  References | X                   |
| Language: The absence of evidence for an effect (eg. non-significant finding in NHST in the literature or the present study) is not treated as evidence for the absence of an effect.   | X                   |
| Language: Causal claims are only permissible where causal evidence is provided. Correlational evidence is not used to support causal claims.  | Х                   |
| Language: There are no policy or intervention recommendations unless (policy) interventions were directly tested in the work.   | Х                   |
| We recommend that authors familiarize themselves with inclusive language guidelines (e.g. https://www.apa.org/about/apa/equity-diversity-inclusion/language-guidelines) and avoid discriminatory language in writing.   | Х                   |
| Methods   |                     |
| The Methods contain sufficient detail such that the work could be repeated by an independent researcher.  All key methods are included in the Methods section in the main manuscript, rather than in the Supplementary Information.   | Х                   |

|   | 07  |
|---|-----|
| All information present in the Reporting Summary is also in the manuscript.   | Х   |
| If there was no preregistration of any study, is declared in the Methods section for transparency. Conversely, if any of the reported studies preregistered, there is an active link to the preregistration in the Methods section and the Methods include a statement about the date of preregistration. All deviations from the preregistered protocol are stated and there is a rationale for each deviation (e.g., flaw, feasibility, suboptimality). In cases of deviation from the preregistered analysis plan for reasons other than fundamental flaw or feasibility, the original planned analyses are reported.  |     |
| If any participants or data points were excluded from the analyses for any reason this is noted with a rationale for the exclusions.  | Х   |
| Where human or non-human participants are involved, confirmation that all relevant ethical regulations were followed is provided. For hu studies, there must be a confirmation that informed consent. This must be stated in the Methods section, including the name of the board institution that approved the study protocol.  If Ethical approval and/or informed consent was waived the reason is included, citing the board and institution to grant this exemption. Ed might ask you to provide additional supporting documentation.  | and |
| Reporting sex and/or gender should follow the SAGER guidelines (https://doi.org/10.1186/s41073-016-0007-6).  Mention how sex/gender were determined (e.g., information provided by participants) in the Methods and Reporting Summary. Age must reported.  Please report whether data on race / ethnicity was collected. If it was, please include the information in the Reporting Summary and in the Methods section.  Other demographics are reported if relevant and only if reporting does not disproportionately the increase risk of identification.  Please also provide information on participant compensation.  Relevant policy: https://www.nature.com/nature-portfolio/editorial-policies/ethics-and-biosecurity#Research-with-human-participants-th data-or-biological-material |     |
| Please ensure that the Methods section includes a statement indicating whether the data met the assumptions of the statistical tests used including whether normality and equal variances were formally tested.   | , Х |
| For Systematic Reviews and Meta-Analyses, please follow the PRISMA guidelines for reporting.  | N/A |
| L   |     |

| Please fully complete a PRISMA checklist (adding information to the manuscript where needed) and upload this with your revised manuscript.   |                     |
|--|---------------------|
| https://prisma-statement.org/PRISMAStatement/Checklist.aspx  |                     |
| For reporting of case reports please follow the CARE guidelines:  Please fully complete the CARE checklist (adding information to the manuscript where needed) and upload this with your revised manuscript.  https://www.care-statement.org/downloads   | N/A                 |
| Please follow the CONSORT extension for N-of-1 trials for reporting of the case report.  | N/A                 |
| Please fully complete the CONSORT N-of-1 checklist (adding information to the manuscript where needed) and upload this with your revised manuscript.  http://www.consort-statement.org/extensions/overview/n-of-1  |                     |
| For the reporting of a clinical trial, please follow the CONSORT 2010 guidelines  Please fully complete a CONSORT 2010 checklist (adding information to the manuscript where needed) and upload this with your revised manuscript. <a href="http://www.consort-statement.org/consort-2010">http://www.consort-statement.org/consort-2010</a> | N/A                 |
| Include the trial registration number from ClinicalTrials.gov or an equivalent agency.   |                     |
| For Clinical Trials involving AI, please follow the guidelines of the CONSORT-AI extension in the reporting of the trial in addition to the core the CONSORT 2010 guidelines.  | N/A                 |
| Please fully complete a CONSORT-AI checklist (adding information to the manuscript where needed) and upload this with your revised manuscript.  https://www.nature.com/articles/s41591-020-1034-x/tables/2   |                     |
| Results  | Author confirmation |
| All statements or interpretations of your results are supported by appropriate, fully reported statistics. Please refer to our specific guidance below.  | X                   |

| Statistics must be reported in full wherever they appear. All references to frequentist inferential statistics must be reported as statistic(degrees of freedom) = value, p = value, effect size statistic = value, % Confidence Intervals = values.  p-values must be reported exact, unless p<0.001.  Don't summarize statistical tests (e.g., all ps<0.0001). List tests separately.   |                     |
|---|---------------------|
| Null effects obtained through NHST must be appropriately reported and cannot be interpreted at all, except if appropriate statistical tests have been employed that allow for meaningful interpretation of the null results.  | X                   |
| NOTE: When reporting null results, you cannot say 'there was no difference' or 'there was no effect'; instead, you must say 'there was no statistically significant difference' or 'there was no statistically significant effect'. Unless, you have used appropriate statistics (e.g., equivalence tests, Bayes factors, etc.), you cannot say anything further about null results and you must refrain from any interpretation. For example, it is inappropriate to say 'There was no statistically significant difference between x and y (p=.342), which suggests that' – a null result in NHST does not suggest anything, except failure to reject the null hypothesis.  This extends to comparisons of relationships between variables – for example, interpretations pertaining to difference of differences are also supported by appropriate statistics¹.  ¹Gelman, A. & Stern, H. The difference between "significant" and "not significant" is not itself statistically significant. Am. Stat. 60, 328–331 (2006). |                     |
| For manuscripts that interpret null results Bayes Factors or equivalence tests that support the null are reported.  | Х                   |
| For manuscripts that interpret null results, the manuscript reports evidence that the study is sufficiently powered to detect the smallest theoretically or pragmatically meaningful effect.  | X                   |
| For Bayesian analyses the manuscript: a) lists specified priors and how they were selected; b) describes the statistical model and the techniques used in the analyses; c) summarizes the posterior distribution with a measure of central tendency and a credibility interval; d) assess the sensitivity of the analyses to different priors.  | Х                   |
| Data & Code Sharing   | Author confirmation |

| <u> </u>   |                     |
|--|---------------------|
| The Data Availability statement includes:  | Х                   |
| Information on all data types used in the study and how they can be accessed.  |                     |
| Accession codes (DOIs/links) for deposited data (public deposition is mandatory for numerical data underlying plots or charts in the manuscript and encouraged for other data).  |                     |
| If applicable, a statement explaining any restrictions on data access. See also https://www.springernature.com/gp/authors/research-data-policy   |                     |
| Code availability  | Х                   |
| Separate from the Data Availability statement, please include a <b>Code Availability statement</b> , indicating how any custom code for this paper can be accessed before the References section; any restrictions to access must be discussed with the editor first and may only subsequently be                          |                     |
| included in the statement. This pertains to analysis code, simulations, and also to the code used to run the experiment, where applicable. This  |                     |
| section should also include information on the versions of any software used, if relevant, and any specific variables or parameters used to generate, test, or process the current dataset.  |                     |
| Please see our policy on code availability for more information. https://www.nature.com/commspsychol/submit/submission-guidelines#code-availability  |                     |
| There must be a competing interests statement that accounts for both financial and non-financial interests, and that the statement does not solely refer to financial interests. See our competing interests policy for further information: https://www.nature.com/nature-research/editorial-policies/competing-interests | Х                   |
| Display items  | Author confirmation |
| Graph axes must originate at 0, cut through 0, or in exceptional cases, include a discontinuity marker.  | Х                   |
| All Figure panels that plot the same measure should be plotted to the same scale unless this obfuscates the data(identical y-axes).  | Х                   |
| Bar graphs should not be used to display measures of central tendency, unless overlayed with single-participant data. Choose graph types showing features of the distribution, e.g. box plots or violin plots rather than bar graphs.  | Х                   |
|  |                     |

| Please include error bars (or equivalent) and define any error bars, shading, box plots etc in each Figure and Supplementary Figure where they are used.  | Х                   |
|---|---------------------|
| Microscopy images and photographs in each Figure and Supplementary Figure must be accompanied by scale bars, and these must be defined. Please add scale bars and corresponding definitions to Specify figure(s).   | N/A                 |
| Please pay close attention to our Digital Image Integrity Guidelines.   |                     |
| Publication of identifiable images of humans in Nature Portfolio journals must be accompanied by a statement attesting that the authors have obtained consent to publication of the images. Images without appropriate consent must be removed.   | N/A                 |
| To obtain consent, you may use the Nature Portfolio form (http://www.nature.com/documents/snl-model-release.docx) or your own consent form, provided the consent meets the conditions set out in the Nature Research consent form.  |                     |
| Supplementary Information File  | Author confirmation |
| Supplementary items must be cited in a consistent format throughout the main text and Supplementary Information. Names of items in the Supplementary file(s) must exactly match those used in the main manuscript. Please cite specific items of the Supplementary Information in the main text (such as Supplementary Figure 1), and not the Supplementary Information in its entirety.  We recommend using the following naming formats: Supplementary Figure 1, Supplementary Table 1, Supplementary Data 1, Supplementary Note 1, and Supplementary References. | Х                   |